Updated:
Hermed Capital
Hermed Capital is a Shanghai-based venture and growth-stage private equity firm investing across seed to late-stage rounds in China.
Hermed Capital
Hermed Capital Fund (通德资本) is a private equity fund focused on investments in China's healthcare industry. The firm has made 13 investments, including a Series A investment in Lukin Medical on July 28, 2023. Hermed Capital has facilitated 4 portfolio exits, with Applied StemCell exiting on October 09, 2023.
General information
Firm type
Private Equity Firm
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
What investment stages does Hermed Capital target?
Hermed Capital's investment mandate spans early-stage seed and start-up rounds through late-stage expansion and growth venture. The firm's public-facing strategy list includes general venture capital as well, indicating a willingness to evaluate companies across multiple financing stages.
Where is Hermed Capital based and does it invest outside China?
Hermed Capital operates from its headquarters in Shanghai, China. The firm's disclosed strategy focuses on Chinese private markets, and no public materials indicate a mandate to invest in other geographies.
Who runs investment decisions at Hermed Capital?
Hermed Capital has not publicly disclosed its investment committee composition or named principals. No team biographies appear on the firm's website or in publicly available regulatory filings.
Does Hermed Capital disclose its assets under management?
No. Hermed Capital does not publicly report an AUM figure. The firm maintains a low public profile with no disclosed fund closes or deployment aggregates, which is typical for a private equity manager that does not actively solicit institutional limited partners.
Is Hermed Capital affiliated with a larger corporate group or family office?
The firm's ownership and capital structure remain opaque in public record. Hermed Capital presents as an independent asset manager, but without disclosed partnership details, the exact nature of its backing — whether third-party institutional, family-linked, or otherwise — cannot be confirmed from available public sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: